The potential of low molecular weight heparin to mitigatie cytokine storm in severe covid-19 patients: a retrospective clinical study

Chen Shi#, Cong Wang#, Hanxiang Wang#, Chao Yang, Fei Cai, Fang Zeng, Fang Cheng, Yihui Liu, Taotao Zhou, Bin Deng, Jinping Li, Yu Zhang*

#Contributed equally

*Corresponding author

Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, China (C Shi PhD, Y Zhang PhD); Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (C Wang MD, H Wang MD, F Zeng MD, F Cheng MD, Y Liu PhD, T Zhou MD, B Deng PhD); Department of Medical Biochemistry and Microbiology , Uppsala University, Uppsala, Sweden (J Li PhD); Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (C Yang MD, F Cai MD)

Correspondence to:

Prof Yu Zhang PhD, Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China, whxhzy@163.com

Summary:

Background On March 11, 2020, the World Health Organization declared its assessment of COVID-19 as a global pandemic. Effective therapeutic drugs are urgently needed to improve the overall prognosis of patients, but currently no such drugs are available.

Methods The basic information, complete blood count, coagulation profile, inflammatory cytokines and serum biochemical indicators in 42 patients with COVID-19 (21 of whom were treated with low molecular weight heparin (LMWH), and 21 without LMWH) were retrospectively analyzed to compare and evaluate the effect of LMWH treatment on disease progression.

Findings 42 patients with COVID-19 treated at the hospital between February 1 and March 15, 2020

were selected for the study, of which 21 underwent LMWH treatment (Heparin group), and 21 did not (Control), during hospitalization. The changes in lymphocyte% in patients in the heparin group before and after LMWH treatment were significantly different to those in the control group (11.10±9.50, 3.08 ±9.66, p=0.011). The changes in D-dimer and fibrinogen degradation products (FDP) levels in the heparin group before and after LMWH treatment were significantly different to those in the control group (-2.85±3.90, -0.05±0.85, p=0.002; -9.05±13.14, -1.78±3.15, p=0.035). In the heparin group, IL-6 levels were significantly reduced after LMWH treatment (47.47±58.86, 15.76±25.71, p=0.006). In addition, the changes in IL-6 levels in the heparin group before and after LMWH treatment were significantly different to those in the control group (-32.46±65.97, 14.96±151.09, p=0.031).

Interpretation In this study, we found that LMWH can improve the coagulation dysfunction of COVID-19 patients, and has anti-inflammatory effects of reducing IL-6 and increasing lymphocyte%, which can be used as a potential therapeutic drug for the treatment of COVID-19 and provide guidance for subsequent clinical treatment.

Introduction

According to *Nature*, the spread of coronavirus disease 2019 (COVID-19) is becoming unstoppable.[1] On March 11, 2020, the World Health Organization (WHO) declared its assessment of COVID-19 as a global pandemic. SARS-CoV-2 is characterized by a long incubation period, high infectivity, and multiple routes of transmission.[2,3] According to real-time WHO statistics, the total number of confirmed cases of COVID-19 worldwide as of April 1, 2020 has exceeded 850,000, with more than 40,000 deaths. However, no effective medicines are currently available, and it can only be treated symptomatically. Given the rapid spread of COVID-19 and the high mortality rate in severe cases, there is an urgent need for a better understanding of its clinical characteristics and may help to screen out reliable specific drugs from marketed drugs.

Lymphopenia and inflammatory cytokine storms are typical abnormalities observed in highly pathogenic coronavirus infections (such as SARS and MERS),[10] and are believed to be associated with disease severity.[5-7] Several clinical studies have observed that cytokine storms are important mechanisms of disease exacerbation and death in COVID-19 patients, .[5-7] Particularly, IL-6 levels in severely ill patients were significantly higher than that in mild cases.[8] IL-6 is one of the core cytokines that are consistently found to be elevated in serum of patients with cytokine storm,[9] it contributes to many of the key symptoms of cytokine storm, i.e. vascular leakage, and activation of the complement

and coagulation cascade inducing disseminated intravascular coagulation (DIC).[10,11] The level of IL-6 is closely related to the occurrence and severity of cytokine storms,reducing the level or activity of IL-6 may contribute to prevent or even reverse the cytokine storm syndrome caused by the virus, [12] thereby improving the condition of patients with COVID-19.

In recent years, a large number of studies have revealed that low molecular weight heparin (LMWH) has various non-anticoagulant properties[13] that play an anti-inflammatory role by reducing the release and biological activity of IL-6.[14-16] However, the anti-inflammatory effects of LMWH in COVID-19 are not currently known. To the best of our knowledge, this is the first retrospective cohort study, to analyze the relieving effect of LMWH in patients with COVID-19. This study aims to review and analyze the treatment course of patients with COVID-19 to investigate the anti-inflammatory effects of heparin and delay disease progression to provide guidance for subsequent clinical practice(Fig.1).

Methods

Research subjects

To investigate the therapeutic effect of LMWH on COVID-19, we conducted a retrospective study. All cases in this study were located at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan, Hubei Province, China), a designated treatment hospital for patients with COVID-19. This study was approved by the institutional review board of the hospital. In total, we retrospectively collected the electronic medical records of 42 patients with COVID-19, the admission data for these patients was from February 1, 2020, to March 15, 2020 (Fig.2 shows the case inclusion flowchart), of which 21 underwent LMWH treatment (Heparin group, Table 1), and 21 did not (Control), during hospitalization.

Inclusion criteria: (1) met the diagnostic standards of novel coronavirus pneumonia (7th edition) formulated by the National Health Commission of China; (2) experienced any of the following: shortness of breath, respiration rate(RR) ≥ 30 breaths/minute; resting oxygen saturation ≤ 93%; PaO2/FiO2 ≤ 300 mmHg; lung imaging showing significant lesion progression by > 50% within 24-48 h, and a severe clinical classification; (3) age ≥ 18 years; (4) no previous history of bronchiectasis, bronchial asthma, or other respiratory diseases; (5) no immunosuppressant or glucocorticoid use during treatment.

Exclusion criteria: (1) patients with severe systemic diseases and other acute or chronic infectious diseases; (2) patients with liver and kidney insufficiency or congenital heart disease; (3) patients who

had been treated with LMWH in the previous three months; (4) patients with a previous history of mental illness; (5) pregnant or lactating women; (6) patients clinically classified as critically ill or housed in the intensive care unit (ICU); (7) patients allergic to LMWH or contraindicated for LMWH.

Data collection

The basic information, complete blood count, coagulation profile, inflammatory cytokines and serum biochemical indicators (including liver function, kidney function, lactate dehydrogenase, C-reactive protein (CRP) and electrolytes) in 42 patients with COVID-19 were retrospectively analyzed. Two researchers also independently reviewed the data collection forms to double check the data collected.

Statistical analysis

Data analysis was performed using SPSS 22.0 statistical software. Data were expressed as mean ± standard deviation (SD). GraphPad 6.0 software was used for plotting. Differences between groups were evaluated using the T-test for measurement data, the Chi-square test for count data, and the Kruskal-Wallis nonparametric test between groups (independent samples) and within groups (related samples). Differences of $p < 0.05$ were considered statistically significant.

Results

General characteristics of patients with COVID-19

As shown in Table 2, the heparin group consisted of 13 males and eight females aged between 42 and 91 years (median age was 69.0 years), and the control group consisted of 14 males and seven females aged between 40 and 84 years (median age was 69.0 years); there was no significant difference between the two groups. There were no significant differences in comorbidities, such as hypertension, diabetes, cardiovascular disease, and carcinomas, between the two groups. Similarly, there were no significant differences in novel coronavirus pneumonia onset symptoms, including fever (body temperature ≥ 37.3°C), cough, sputum, chest distress or asthma, myalgia, fatigue, anorexia, diarrhea, and nausea and vomiting. Similarly, there was no significant difference in antiviral treatment between the two groups. These results indicate that the general characteristics of the two groups of patients were consistent and comparable.

LMWH has no effect on the days to conversion to negative and the duration of hospitalization of patients with COVID-19

As shown in Table 2, the number of days to conversion to negative (time from hospitalization to virus shedding) was 20.0 days (IQR 11.0-31.0) in the heparin group and 19.0 days (IQR 12.0-30.0) in the

control group (p = 0.46); the difference between the two groups was not significant. Similarly, the length of hospital stay was 29.0 days (IQR 17.0-42.0) in the heparin group and 27.0 days (IQR 24.0-31.0) in the control group (p = 0.41); the difference between the two groups was not significant. Notably, all patients showed improvement after treatment.

Effect of LMWH on Blood routine in patients with COVID-19

As shown in Fig.3A-D, there was no significant difference in red blood cells (RBC), white blood cells (WBC), monocyte% and neutrophil% levels between the two groups. As shown in Fig.3E, there was no significant difference in lymphocyte% between the heparin and control groups before treatment (18.84 ±8.24, 22.42±8.74, *p*=0.144). There was no significant difference in lymphocyte% between the heparin and control groups after treatment (29.94±7.92, 25.65±10.10, *p*=0.215). However, patients in the heparin group had a significantly increased percentage of lymphocytes after LMWH treatment (18.84± 8.24, 29.94±7.92, *p*=0.000). In addition, the changes in lymphocyte% in patients in the heparin group before and after LMWH treatment were significantly different to those in the control group (11.10± 9.50, 3.08±9.66, *p*=0.011).

Effect of LMWH on coagulation function in patients with COVID-19

According to the data, there was no significant difference in thrombin time (TT, Fig.3F), activated partial thromboplastin time (APTT, Fig.3G), prothrombin time (PT, Fig.3H) levels between the two groups. As shown in Fig.3I, the levels of D-dimer in the heparin group were significantly higher compared to those in the control group before treatment (3.75±4.04, 1.23±1.15, *p*=0.009). There was no significant difference in D-dimer levels between the heparin and control groups after treatment (0.90 ±0.44, 1.00±1.06, *p*=0.368). In the heparin group, D-dimer levels were significantly reduced after LMWH treatment (3.75±4.04, 0.90±0.44, *p*=0.001). The changes in D-dimer levels in patients in the heparin group before and after LMWH treatment were significantly different to those in the control group (-2.85±3.90, -0.05±0.85, *p*=0.002). As shown in Fig.3J, the levels of fibrinogen degradation products (FDP) in the heparin group were significantly higher compared to those in the control group before treatment (14.35±14.6, 4.05±3.9, *p*=0.002). There was no significant difference in FDP levels

between the heparin and control groups after treatment (2.64±1.16, 3.59±4.00, p=0.959). In the heparin group, FDP levels were significantly reduced after LMWH treatment (14.35±14.6, 2.64±1.16, p=0.001). The changes in FDP levels in patients in the heparin group before and after LMWH treatment were significantly different to those in the control group (-9.05±13.14, -1.78±3.15, p=0.035). However, there was no significant difference in fibrinogen (FIB, Fig.3K), antithrombin □ (AT □, Fig.3L) and international normalized ratio (INR, Fig.3M) levels between the two groups.

Effect of LMWH on CRP in patients with COVID-19

As shown in Fig.3N, there were no significant differences in CRP levels between the two groups of patients before treatment (31.15±26.62, 29.00±23.79, p=0.497). There were no significant differences in CRP levels between the two groups of patients after treatment (8.95±10.44, 8.76±16.66, p=0.620). Similarly, there were no significant differences in the changes of CRP levels between the two groups of patients before and after LMWH treatment (-22.62±23.79, -20.23±33.91, p=0.660).

Effect of LMWH on cytokines in patients with COVID-19

As shown in Fig.4, we performed statistical analyses on the levels of inflammatory cytokines in the two groups. There were no significant differences in the levels of IL-2, IL-4, IL-10, TNF-α and IFN-γ between the two groups. Notably, there was no significant difference in IL-6 levels between the heparin and control groups before treatment (47.47±58.86, 63.27±96.27, p=0.950). The levels of IL-6 in the heparin group were significantly lower compared to those in the control group after treatment (15.76±25.71, 78.24±142.41, p=0.000). In the heparin group, IL-6 levels were significantly reduced after LMWH treatment (47.47±58.86, 15.76±25.71, p=0.006). Similarly, the changes in IL-6 levels in the heparin group before and after LMWH treatment were significantly different to those in the control group (-32.46±65.97, 14.96±151.09, p=0.031).

Discussion

Cytokine storms are associated with deterioration in several infectious diseases, including SARS and avian influenza,[4,17] and are an important mechanism of exacerbation in patients.[18] In recent years,

studies have revealed that heparin has various non-anticoagulant properties, for instance LMWH can exert anti-inflammatory effects by reducing the release and biological activity of IL-6.[14-16,19]

Meanwhile some results indicate that IL-6 and IL-8 can cause hypercoagulation, leading to scattered fibrin clots, shortening the clot dissolution time and maximum dissolution rate.[20] Several clinical researches have observed that severe COVID-19 patients had higher levels of IL-6,[8] which suggests the hypercoagulation status of COVID-19 patients may be related to the body increased cytokine levels. In previous studies of patients with COVID-19, D-dimer levels were significantly elevated in patients admitted to the ICU with severe cases.[21] The research of Ning Tang et al. showed higher levels of D-dimer and FDP in fatal cases,[22] and Li *et al.* believe that while monitoring for venous thromboembolism, there may have some correlation between D-dimer and COVID-19 severity.[23] However, there is currently no conclusive evidence supporting the use of D-dimer as an evaluation index.[24-26] A large sample analysis is required to determine whether D-dimer is associated with COVID-19 severity. Therefore, the present study does not consider this parameter as an evaluation index for disease progression. The average values of D-dimer and FDP before treatment was greater in the heparin group than in the control group (3·75,1·23,P < 0.01;14·35,4·05,P < 0·01). Because this trial is a retrospective analysis, we did not intervene in the drug use of the patients, it can be inferred that the purpose of medication in the heparin group is to improve hypercoagulability. Because D-dimer and FDP are not considered as factors for the patient's disease progression, therefore, it has no effect on subsequent analysis of results.

Several studies have recommended CRP and lymphocyte%(LYM%)as indices for evaluating the effectiveness of clinical drugs or treatments.[27-29] In the difference analysis of this study, there was no statistically significant difference in CRP between the groups, indicating that LMWH treatment has no effect on this parameter, but in the result of LYM%, the mean value of the heparin group was higher than that of the control group (11·10% and 3·08%, respectively). LYM% was higher in the heparin group after treatment compared to the control group ($p < 0·001$), which is consistent with the results of Derhaschnig *et al.*[30] This suggests that LMWH can increase LYM% in patients with COVID-19 and improve their condition. There are two possible reason: First, SARS-CoV-2 is highly homologous to SARS-CoV, heparan sulfate proteoglycans(HSPGs) is the basic cell surface molecule involved in SARS-CoV cell entry,[31] and LMWH is a member of the HSPGs family,[32] it has already been confirmed that the addition of exogenous heparin reduced the ability of SARS-CoV to bind to the cell surface and increased cellular resistance to infection.[33,34] Mycroft-West *et al.* also showed that LMWH can bind to the SARS-CoV-2 surface protein (Spike) S1 receptor binding domain and block the replication of the virus, thus, showing potential antiviral effects.[35] Additionally, LMWH can reduce lymphocyte death caused by the direct viral infection of lymphocytes.[6] The second, preliminary research has confirmed that proinflammatory cytokines, such as TNFα and IL-6, can induce lymphopenia.[7] Therefore,

decreases in the number or activity of relevant inflammatory factors may have some significance for the increase in LYM%.

IL-6 levels in severely ill patients with COVID-19 are significantly higher than in patients with mild cases,[8] and a cytokine storm may occur when cytokines reach a certain threshold in the body.[9] The transition from a mild to severe condition in patients with COVID-19 may be caused by cytokine storms. Reducing IL-6 release or activity may prevent the cytokine storm syndrome caused by the virus,[10] thereby improving the condition of patients with COVID-19. Studies have shown that LMWH may reduce the release of IL-6 in the body by inhibiting the expression of nuclear factor κB (NF-κB).[14-16] In the present study, we performed statistical analysis of the levels of inflammatory cytokines in two groups of patients, and the results showed that IL-6 significantly decreased in the heparin group compared to the control group, whereas the changes in other inflammatory factors were not statistically significant; these results are consistent with the conclusions above. In addition, a study by Mummery *et al.* found that heparincan bind to IL-6, it may serve to reduce the availability of IL-6 to its receptor complex, including IL-6 binding to SIL-6R and IL-6 /SIL-6R binding to sgp130,[19] this may reduce the the biological activity of IL-6. This indicates that LMWH reduces the release of IL-6 while also reducing its biological activity, which also explains the increase of LYM% in the heparin group.

This study found that LMWH can improve the coagulation dysfunction of COVID-19 patients, and has anti-inflammatory effects of reducing il-6 and increasing LYM%, which can be used as a potential therapeutic drug for the treatment of COVID-19 and provide guidance for subsequent clinical treatment. In addition, to further confirm the conclusions of this study, we conducted a prospective clinical study to evaluate the efficacy and safety of enoxaparin sodium in the treatment of hospitalized adult patients with COVID-19(Chinese Clinical Trial Registry ,number:chiCTR2000030700), with the expectation of providing a more powerful reference for treatment.

Limitations:

This study has some limitations. First, due to the retrospective design, we were unable to control the time intervals between examinations of various indices in patients and the LMWH dosing schedule, and we could not estimate the effective dose and timing of LMWH. Second, there were no critical cases in the two groups of patients in the trial; the treatment outcome of all cases was improvement and discharge and there were no deaths. Therefore, the reference value for the treatment outcomes of critically ill patients was limited. Finally, the sample size and single-center design may have limited our findings.

Contributors

CS, JP and YZ conceptualized and designed the study, and CS and YZ had full access to all data, and

took responsibility for data integrity and accuracy of the analysis. CS, CW and HX wrote the manuscript. CY, FC and FZ reviewed the manuscript. FC, YH, TT and BD performed the statistical analysis. All authors contributed to data acquisition, analysis and interpretation, and approved the final version for submission.

Declaration of interests

All authors declare no competing interests.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 81603037 to SC) and the National Key Research and Development Plan of China(2017YFC0909900).

Patient consent for publication Not required

Ethics approval The human study was approved the Research Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

References:

1. Callaway E. Time to use the p-word? Coronavirus enter dangerous new phase. Nature 2020; 579: 12.

2. Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet. 2020, 395(10223):470-473.

3. Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395(10223):497-506.

4. De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–534.

5. Zhou W, Liu YS, Tian DD, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduction and Targeted Therapy. 2020;5:18.

6. Li Tan, Qi Wang, Duanyang Zhang, et al. Lymphopenia predicts diseaseseverity of COVID-19:a descriptive and predictive study. MedRxiv.2020.03.01.20029074.

7. Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol. 2002;169(8): 4288-97.

8. Wan SX, Yi QJ, Fan SB, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv. 2020[2020-02-24].

9. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.

10. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959-970.

11. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16:448-457.

12. Teachey DT, Lacey SF, Shaw PA, et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016;6(6):664-679.

13. Wang QL, Shang XY, Zhang SL, et al. Effects of inhaled low molecular weight heparin on airway allergic inflammation in aerosol-ovalbumin-sensitized guinea pigs. Jpn J Pharmacol. 2000;82(4):326-330.

14. Qian Y, Xie H, Tian R, Yu K, Wang R. Efficacy of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. COPD. 2014;11(2):171-176.

15. Yina Liu, Shengtian Mu, Xu Li, Yingjian Liang, Liang Wang, Xiaochun Ma. Unfractionated Heparin Alleviates Sepsis-Induced Acute Lung Injury by Protecting Tight Junctions. J Surg Res. 2019;6(238): 175-185.

16. Li X, Ma Y, Chen T, Tang J, Ma X. Unfractionated heparin inhibits lipopolysaccharide-induced expression of chemokines in human endothelial cells through nuclear factor-κB signaling pathway. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2016;28(2):117-121.

17. Dongmei Rao. Research progress on cytokine storm induced by pathogen infection. Medical Information. 2014;27(2):480-481.

18. Qian Chen, Yao Wang, Fangzhou Jiao, et al. Discussion on the mechanism and intervention strategy of inflammatory storm of new coronavirus pneumonia. Chinese Journal of Infectious Diseases. 2020;38(2020-02-26).

19. Mummery RS, Rider CC. Characterization of the heparin-binding properties of IL-6. J Immunol.

2000;165(10):5671-5679.

20. Bester J, Matshailwe C, Pretorius E. Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β, IL-6 and IL-8. Cytokine. 2018;110:237-242.

21. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

22. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia [published online ahead of print, 2020 Feb 19]. J Thromb Haemost. 2020;10.1111/jth.14768.

23. Li XY, Du B, Wang YS, et al. The keypoints in treatment of the critical coronavirus disease 2019 patient. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 29;43(0):E026.[Online ahead of print].

24. Querol-Ribelles JM, Tenias JM, Grau E, et al. Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest. 2004;126(4):1087-1092.

25. Snijders D, Schoorl M, Bartels PC,et al. D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial. Eur J Intern Med. 2012;23(5):436-441.

26. Duarte JC, Tavares e Castro A, Silva R, et al. Prognostic value of plasma D-dimer level in adults with community-acquired pneumonia: a prospective study. Rev Port Pneumol (2006). 2015;21(4):218-219.

27. Fei Zhou, Ting Yu, Ronghui Du, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 12:S0140-6736(20)30606-1. Online ahead of print.

28. Li Tan, Qi Wang, Duanyang Zhang, et al. Lymphopenia predicts diseaseseverity of COVID-19:a descriptive and predictive study. MedRxiv.2020.03.01.20029074.

29. Xun Li, Luwen Wang, Shaonan Yan.et al. Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China. MedRxiv. 2020.02.25.

30. Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, Hollenstein U, Panzer S, Jilma B. Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Crit Care Med. 2003;31(4):1108-1112.

31. Belting M. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends in biochemical

sciences. 2003;28:145–151.

32. Casu B, Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem. 2001;57:159–206.

33. Vicenzi E, Canducci F, Pinna D, et al. Coronaviridae and SARS-associated coronavirus strain HSR1. Emerg Infect Dis. 2004;10(3):413-8.

34. Lang J, Yang N, Deng J, et al. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS One. 2011;6(8):e23710.

35. Courtney Mycroft-West , Dunhao Su, Stefano Elli, et al . The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding. BioRxiv preprint.

Figure captions

Figure 1. Possible mechanism of anti-inflammatory effects of LMWH in patients with COVID-19.

Under conventional antiviral treatment regimens, LMWH improves hypercoagulability, inhibits IL-6 release, and counteracts IL-6 biological activity in patients. It has potential antiviral effects and helps delay or block inflammatory cytokine storms. LMWH can increase the LYM% of patients and may be suitable as treatment for COVID-19.

Figure 2. Flowchart of inclusion and exclusion criteria for patients with COVID-19.

Based on strict inclusion and exclusion criteria, 42 patients with COVID-19 treated at the hospital between February 1 and March 15, 2020 were selected for the study, of which 21 underwent LMWH treatment (Heparin group) and 21 did not (Control) during hospitalization.

Table 1. LMWH use in the 21 patients with COVID-19.

Details of the dose, frequency, route of administration, and days of use of LMWH in the heparin group.

Table 2. General characteristics of all the patients with COVID-19.

There were no significant differences in age, sex, comorbidities, onset symptoms, time from hospitalization to virus shedding, length of hospital stay, antiviral treatment and disease progression between the two groups. Data are median (IQR) or n(%). p values are comparing heparin group and control. NA=not applicable.

Figure 3. Effect of LMWH on complete blood count, coagulation profile and CRP in patients with COVID-19.

(A-N) Red blood cells (A), white blood cells (B), monocytes% (C), neutrophils% (D), lymphocytes% (E), TT (F), APTT (G), PT (H), D-dimer (I), FDP (J), FIB (K), AT III (L), INR (M) and CRP (N) levels in patients with COVID-19. Data are expressed as mean ± standard deviation (SD) (n = 21). C1 vs. H1 or C2 vs. H2, ^{a} $p < 0.05$, ^{aa} $p < 0.01$, ^{aaa} $p < 0.001$; C1 vs. C2 or H1 vs. H2, ^{b} $p < 0.05$, ^{bb} $p < 0.01$, ^{bbb} $p < 0.001$; C3 vs. H3, ^{c} $p < 0.05$, ^{cc} $p < 0.01$, ^{ccc} $p < 0.001$. (C1: control group, indices at admission; C2: control group, indices at discharge; C3: control group, changes in indices during hospitalization; H1: heparin group, indices before LMWH treatment; H2: heparin group, indices after LMWH treatment; H3: heparin group, changes in indices before and after LMWH treatment.).

Figure 4. Effect of LMWH on inflammatory cytokines in patients with COVID-19.

(A-F) IL-2 (A), IL-6 (B), TNF-α (C), IL-4 (D), IL-10 (E), and IFN-γ (F) levels in the two groups of patients with COVID-19. Data are expressed as mean ± standard deviation (SD) (n = 21). C1 vs. H1 or C2 vs. H2, ^{a} $p < 0.05$, ^{aa} $p < 0.01$, ^{aaa} $p < 0.001$; C1 vs. C2 or H1 vs. H2, ^{b} $p < 0.05$, ^{bb} $p < 0.01$, ^{bbb} $p < 0.001$; C3 vs. H3, ^{c} $p < 0.05$, ^{cc} $p < 0.01$, ^{ccc} $p < 0.001$. (C1: control group, indices at admission; C2: control group, indices at discharge; C3: control group, changes in indices during hospitalization; H1: heparin group, indices before LMWH treatment; H2: heparin group, indices after LMWH treatment; H3: heparin group, changes in indices before and after LMWH treatment.)


SARS-CoV-2 entry
Receptor ACE2
Binding interaction and preventing virus invasion
Endothelial Cells
NF-κB
Inhibiting the NF-κB pathway and reducing the release of IL-6
Monocyte
T- Cell
Macrophage
B-Cell
LMWH
IL-6
Binding interaction and decreasing the activity of IL-6
IL-6 receptor
Inactive T Cell
NK Cell
Activated B cell
Cytokine storm
Activate
Inhibit
Release


Hospitalized patients
Inclusion criteria:
①Patients were diagnosed as COVID-19 according to the New Coronavirus Pneumonia Diagnosis Program (7th edition) published by the National Health Commission of China;
②The clinical classification was severe, including any of the following: shortness of breath, RR ≥30 bpm, blood oxygen saturation ≤93% (at rest), PaO2/FiO2≤300 mmHg, or pulmonary inflammation that progresses significantly within 24 to 48 hours ＞50%;
③Age ≥18 years old;
④Patients with no previous respiratory diseases such as bronchiectasis and bronchial asthma;
⑤Patients who had not received immunosuppressive agents and glucocorticoid therapy during hospitalization.
Exclusion criteria:
①Patients with severe systemic diseases and other acute/chronic infectious diseases;
②Patients with liver/kidney dysfunction and congenital heart disease;
③Patients who received LMWH treatment within the last three months;
④Patients with a previous history of mental illness;
⑤Pregnant or lactating women;
⑥Critical patients or patients requiring ICU care;
⑦Patients with allergy to LMWH or contraindication to LMWH.
Patients who received LMWH treatment during hospitalization（Heparin Group, n=21）
Patients who were not treated with LMWH during hospitalization（Control, n=21）

Heparin Group (n=21)	Treatment with LMWH	Days of treatment
H1	Enoxaparin sodium injection 4000AxaIU qd i.h.	10
H2	Enoxaparin sodium injection 4000AxaIU qd i.h.	10
H3	Enoxaparin sodium injection 4000AxaIU qd i.h.	14
H4	Enoxaparin sodium injection 4000AxaIU qd i.h.	13
H5	Enoxaparin sodium injection 4000AxaIU qd i.h.	17
H6	Nadroparin calcium injection 4100AxaIU qd i.h.	9
H7	Enoxaparin sodium injection 4000AxaIU qd i.h.	2
H8	LMWH sodium injection 5000IU once i.h.	1
H9	Enoxaparin sodium injection 4000AxaIU qd i.h.	16
H10	Enoxaparin sodium injection 4000AxaIU qd i.h.	19
H11	Enoxaparin sodium injection 4000AxaIU qd i.h.	14
H12	Enoxaparin sodium injection 2000AxaIU qd i.h.	19
H13	Enoxaparin sodium injection 2000AxaIU qd i.h.	22
H14	Nadroparin calcium injection 4100AxaIU qd i.h.	11
H15	Nadroparin calcium injection 4100AxaIU qd i.h.	13
H16	Enoxaparin sodium injection 4000AxaIU qd i.h.	8
H17	Nadroparin calcium injection 4100AxaIU qd i.h.	19
H18	LMWH sodium injection 5000IU qd i.h.	8
H19	Enoxaparin sodium injection 4000AxaIU qd i.h.	8
H20	Enoxaparin sodium injection 4000AxaIU qd i.h.	7
H21	Enoxaparin sodium injection 4000AxaIU qd i.h.	10

	Heparin Group (n=21)	Control (n=21)	p value
Characteristics			
Age, years	69.0(42.0-91.0)	69.0(40.0-84.0)	0.54
Sex	-	-	0.75
Female	8(38%)	7(33%)	-
Male	13(62%)	14(67%)	-
Comorbidity	13(62%)	8(38%)	0.12
Hypertension	8(38%)	5(24%)	0.32
Diabetes	6(29%)	2(10%)	0.12
Cardiovascular disease	5(24%)	2(10%)	0.21
Chronic obstructive lung disease	0	0	NA
Carcinoma	0	1(5%)	0.31
Chronic kidney disease	0	0	NA
Other	4(19%)	1(5%)	0.15
Signs and symptoms			
Fever (temperature ⩾37.3°C)	15(71%)	13(62%)	0.51
Cough	9(43%)	7(33%)	0.53
Sputum	6(29%)	4(19%)	0.47
Chest distress or asthma	11(52%)	8(38%)	0.35
Myalgia	2(10%)	3(14%)	0.63
Fatigue	8(38%)	5(24%)	0.32
Anorexia	6(29%)	5(24%)	0.73
Diarrhoea	2(10%)	1(5%)	0.55
Nausea or vomiting	2(10%)	1(5%)	0.55
Respiratory rate ⩾30 breaths per min	0	0	NA
Pulse ⩾125 beats per min	0	0	NA
Systolic blood pressure ＜90 mmHg	0	0	NA
Antiviral therapy			
Arbidol	18(86%)	20(95%)	0.29
Recombinant Human Interferon α2B (aerosol inhalation)	6(29%)	6(29%)	1.00
Ribavirin	2(10%)	0	0.15
Lopinavir/Ritonavir	2(10%)	0	0.15
Traditional Chinese medicine decoction	11(52%)	9(43%)	0.54
Disease progression			
Improved	21(100%)	21(100%)	NA
Invariable	0	0	NA
Deteriorative	0	0	NA
Time from hospitalization to virus shedding after the onset of the COVID-19, days	20.0(11.0-31.0)	19.0(12.0-30.0)	0.46
Hospital length of stay, days	29.0(17.0-42.0)	27.0(24.0-31.0)	0.41


A
Red cells (×10^12/L)
B
White cells (×10^9/L)
C
Monocytes (%)
D
Neutrophils (%)
ns
E
Lymphocytes (%)
bbb
c
F
TT (s)
b
G
APTT (s)
ns
H
PT (s)
b
ns
I
D-Dimer (mg/L)
ns
ns
aa
J
FDP (mg/L)
ns
ns
c
K
FIB (g/L)
ns
L
ATIII (%)
M
INR
b
a
N
C-reactive protein (mg/L)
ns
ns
C1
H1
C2
H2
C3
H3


A
IL-2 (ng/L)
bbb
bbb
C1
H1
C2
H2
C3
H3
B
IL-6 (ng/L)
aaabb
c
C1
H1
C2
H2
C3
H3
C
TNF-α (ng/L)
bb
C1
H1
C2
H2
C3
H3
D
IL-4 (ng/L)
bbb
b
C1
H1
C2
H2
C3
H3
E
IL-10 (ng/L)
bbb
b
C1
H1
C2
H2
C3
H3
F
IFN-γ (ng/L)
bbb
bbb
C1
H1
C2
H2
C3
H3